PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer

Okuda, Yohei; Kato, Taigo; Ishizuya, Yu et al.

International Journal of Urology, 2025

アクセス数:71件（2025-08-14 20:40 集計）

固定URL: https://hdl.handle.net/11094/102228

閲覧可能ファイル 

ファイル フォーマット 利用条件 サイズ 閲覧回数 利用開始日 説明 information
IntJofUrology pdf なし 237 KB 9 2025.07.10  
Creative Commons : 表示 - 非営利 - 改変禁止

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル
PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer
著者
NRID
1000010964372 1000010964372
ORCID
0000-0001-9909-4200 0000-0001-9909-4200
researchmap permalink
okudayohei okudayohei
著者名
Okuda, Yohei
NRID
1000070648021 1000070648021
researchmap permalink
taigokato taigokato
Scopus Author ID
55414697500 55414697500
ORCID
0000-0002-8681-1407 0000-0002-8681-1407
著者名
Kato, Taigo
NRID
1000000783854 1000000783854
researchmap permalink
okiishi okiishi
著者名
Ishizuya, Yu
NRID
1000050747079 1000050747079
researchmap permalink
takuhaya takuhaya
著者名
Hayashi, Takuji
NRID
1000090759557 1000090759557
researchmap permalink
yoshi229 yoshi229
ORCID
0000-0002-1271-3521 0000-0002-1271-3521
著者名
Yamamoto, Yoshiyuki
NRID
1000060762234 1000060762234
researchmap permalink
koji_hatano koji_hatano
Scopus Author ID
14627167600 14627167600
著者名
Hatano, Koji
NRID
1000050746568 1000050746568
researchmap permalink
akawashima akawashima
Scopus Author ID
9846139400 9846139400
著者名
Kawashima, Atsunari
NRID
1000060532603 1000060532603
著者名
Murai, Junko
NRID
1000030263263 1000030263263
researchmap permalink
read0185096 read0185096
Scopus Author ID
7005880662 7005880662
著者名
Nonomura, Norio
内容
Okuda Yohei, Kato Taigo, Ishizuya Yu, et al. PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer. International Journal of Urology (2025); https://doi.org/10.1111/iju.70100.
抄録
Alterations in the homologous recombination repair genes, such as BRCA1 and BRCA2, are prevalent in various cancers, presenting a unique opportunity to develop synthetic lethal strategies that target homologous recombination deficiency (HRD). Poly ADP-ribose polymerase inhibitors (PARPis) have been developed to induce synthetic lethality in tumors with HRD by inhibiting the repair of single-strand DNA breaks. Beyond the initial approach to target cancers associated with HRD, the utility of PARPis has expanded to combination therapy with immune checkpoint inhibitors, anti-angiogenic drugs, or anti-androgen drugs based on the molecular biological rationale. In the field of genitourinary (GU) cancer, PARPis, such as olaparib, rucaparib, and talazoparib, are approved by the Food and Drug Administration in metastatic prostate cancer patients with BRCA1/2 mutations, sometimes in combination with other agents (e.g., olaparib plus abiraterone acetate, or talazoparib plus enzalutamide). More recently, pivotal clinical trials have broadened the potential of PARPis to the other GU cancers, including urothelial carcinoma and renal cell carcinoma. In this review, we examine the biomarkers for the response to PARPis beyond mutations in BRCA1/2 and discuss the current state and future perspectives of PARPis in GU cancers.
出版者
Wiley
収録物名
International Journal of Urology
刊行年月
2025-06-09
言語
英語
ハンドルURL
https://hdl.handle.net/11094/102228
PISSN
09198172
eISSN
14422042
関連情報 (isIdenticalTo)
DOI (出版社版)
https://doi.org/10.1111/iju.70100
アクセス権
open access
権利情報
© 2025 The Author(s). International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association.
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
出版タイプ
Version of Record
カテゴリ
学術雑誌論文 Journal Article